MADRID, 10 December (MAIN EUROPA) –
The only remedy of trastuzumab emtansine, registered by Roche by name Kadcyla, is to reduce the risk of a 50% return or death, compared to trastuzumab (& # 39; Herceptin & # 39;), as an advanced medicine (after surgery) in patients with HER2's early chronic breast cancer (a long-term illness (Continuous Illness) ; chnoc and nalan lymph axile) after non-advanced treatment, according to the results of stage III analysis and Katherine.
At three years, 88.3% of patients were not treated by Kadcyla & # 39; without recycling compared to 77 per cent received by Herceptin, representing a 11.3 per cent development.
In addition, Kadcyla & # did; improving their living disorder out of the attack, despite the status of the hormone receptor and the winding habits, as well as the curative government; formerly opposed to HER2 received before it went.
"The results of this survey show a significant reduction in the risk of this type of recyclable cancer early recycling in people with continuous diseases after non-advanced treatment, and we expect send this data to the health authorities as soon as possible. With each of those advances that reduce the appeal of illness, we are getting closer and closer to the aim of helping all patients with early cancer and cookie to have a greater chance of cure, "said the chief remedial officer and is responsible for Roche's Universal Product Development, Sandra Horning.
These results were recently donated in a vocal session at the San Antonio Cansa System, as part of the official media program, and was published, at the same time, in the New England Journal of Medicine (NEJM).